person · Reporting owner
Prentiss Christopher B
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MANNKIND CORPMNKD · Entity 4792 | Chief Financial Officer | July 15, 2026 | July 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MANNKIND CORP
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 329,343 |
Reported balance
After 2026-07-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-15 · Tax withholding · Disposed 11,572 · Balance 329,343 F1: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. F2: Includes 1,991 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 318,668 |
Reported balance
After 2026-07-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-15 · Tax withholding · Disposed 10,675 · Balance 318,668 F1: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
F2: Includes 1,991 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Adamas Pharmaceuticals Inc
Report date November 24, 2021 · Filed November 24, 2021
Section 16 reporting ended · disclosed 2021-11-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-11-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-11-24 · Grant · Acquired 18,750 · Balance 163,767 F1: Represents shares of performance-based restricted stock units ("PRSUs") granted to the reporting person on March 2, 2021. The performance conditions associated with the PRSUs had not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the PRSU was deemed to have vested. Row 2 · 2021-11-24 · Other · Disposed 163,767 · Balance 0 F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F3: A portion of this amount consists of unvested restricted stock units, including PRSUs ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price. F4: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.81 · Expires 2029-04-07 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-24 · Disposition to issuer · Disposed 37,500 · Balance 0 F7: $1.29 plus two CVRs per share underlying the stock option. F5: The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with May 1, 2019, subject to Reporting Person's Continuous Service as of each such date. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2029-11-06 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-24 · Disposition to issuer · Disposed 50,000 · Balance 0 F9: $3.40 plus two CVRs per share underlying the stock option. F8: The Option shares shall vest as follows: 1/48th of the option shares shall vest on December 1, 2019 and 1/48th shall vest monthly thereafter, subject to Reporting Person's Continuous Service as of each such date. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of performance-based restricted stock units ("PRSUs") granted to the reporting person on March 2, 2021. The performance conditions associated with the PRSUs had not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the PRSU was deemed to have vested.
F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price").
F3: A portion of this amount consists of unvested restricted stock units, including PRSUs ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price.
F4: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value.
F5: The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with May 1, 2019, subject to Reporting Person's Continuous Service as of each such date.
F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.
F7: $1.29 plus two CVRs per share underlying the stock option.
F8: The Option shares shall vest as follows: 1/48th of the option shares shall vest on December 1, 2019 and 1/48th shall vest monthly thereafter, subject to Reporting Person's Continuous Service as of each such date.
F9: $3.40 plus two CVRs per share underlying the stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 18, 2026 01:47 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 10,675 | $4.09 | $43,660.75 |
DisclosureSEC source: 0001193125-26-308139 · ownership.xml · nonDerivative · entry 2 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,668 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:47 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 11,572 | $4.09 | $47,329.48 |
DisclosureSEC source: 0001193125-26-308139 · ownership.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,343 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. F2 · balance_after: Includes 1,991 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. Read SEC document |
| April 22, 2026 Filed Apr 25, 2026 01:30 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 12,267 | $2.74 | $33,611.58 |
DisclosureSEC source: 0001193125-26-178298 · ownership.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,924 F1 · shares: Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 15, 2024. F2 · balance_after: Includes 2,337 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2025. Read SEC document |
| March 23, 2026 Filed Mar 26, 2026 01:30 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 217,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001193125-26-124726 · ownership.xml · derivative · entry 2 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,000 Underlying: Common Stock, $0.01 Par Value · 217,000 shares Expires 2036-03-23 F3 · derivative.exercise_date: 25% vesting on March 23, 2027 and thereafter 1/16th quarterly. Read SEC document |
| March 23, 2026 Filed Mar 26, 2026 01:30 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 221,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-124726 · ownership.xml · derivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,000 Underlying: Common Stock, $0.01 Par Value · 221,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F2 · derivative.expiration_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 5,000 | $3.27 | $16,350.00 |
DisclosureSEC source: 0001193125-26-089611 · ownership.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,854 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan. The purchase was approved by the Company's Board of Directors on March 1, 2026. Read SEC document |
| July 15, 2025 Filed Jul 18, 2025 00:45 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 11,540 | $3.85 | $44,429.00 |
DisclosureSEC source: 0000950170-25-096735 · ownership.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,854 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. F2 · balance_after: Includes 2,201 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025. Read SEC document |
| May 13, 2025 Filed May 16, 2025 00:34 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 145,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073046 · ownership.xml · derivative · entry 2 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock, $0.01 Par Value · 145,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 13, 2025 Filed May 16, 2025 00:34 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 119,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073046 · ownership.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 353,193 F1 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F4 · balance_after: Includes 1,593 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2024. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 158,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062064 · ownership.xml · derivative · entry 3 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,000 Underlying: Common Stock, $.01 Par Value · 158,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F4 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F4 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062064 · ownership.xml · nonDerivative · entry 2 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,600 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 103,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062064 · ownership.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,600 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: 4-year vesting schedule with 1/4th of shares vesting on the first anniversary of the vesting determination date and on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date. The vesting determination date for this grant is April 22, 2024. Read SEC document |
| May 15, 2024 Filed Mar 29, 2025 00:20 UTC Amendment | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 103,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-047091 · ownership.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,600 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Correction of vesting: 4-year vesting schedule with 1/3rd of shares vesting on the second anniversary of the vesting determination date of April 22, 2024 and on each anniversary thereafter until fully vested. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 16:10 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001328143-21-000092 · wf-form4_163778819925663.xml · derivative · entry 4 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2029-11-06 F9 · price: $3.40 plus two CVRs per share underlying the stock option. F8 · derivative.exercise_date: The Option shares shall vest as follows: 1/48th of the option shares shall vest on December 1, 2019 and 1/48th shall vest monthly thereafter, subject to Reporting Person's Continuous Service as of each such date. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 16:10 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | Disposition to issuerStock Option (Right to Buy) · Derivative | 37,500 | Not disclosed Strike: $6.81 | Not disclosed |
DisclosureSEC source: 0001328143-21-000092 · wf-form4_163778819925663.xml · derivative · entry 3 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2029-04-07 F7 · price: $1.29 plus two CVRs per share underlying the stock option. F5 · derivative.exercise_date: The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with May 1, 2019, subject to Reporting Person's Continuous Service as of each such date. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 16:10 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | OtherCommon Stock | 163,767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001328143-21-000092 · wf-form4_163778819925663.xml · nonDerivative · entry 2 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F3 · shares: A portion of this amount consists of unvested restricted stock units, including PRSUs ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price. F4 · price: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 16:10 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001328143-21-000092 · wf-form4_163778819925663.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,767 F1 · shares: Represents shares of performance-based restricted stock units ("PRSUs") granted to the reporting person on March 2, 2021. The performance conditions associated with the PRSUs had not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the PRSU was deemed to have vested. Read SEC document |
| March 22, 2021 Filed Mar 23, 2021 18:02 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 2,422 | $5.48 | $13,272.56 |
DisclosureSEC source: 0001209191-21-022631 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,017 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $5.40 to $5.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 16:56 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016939 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,439 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 1/3rd of the total number of Restricted Stock Units will vest on each of March 1, 2022, March 1, 2023 and March 1, 2024, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| February 01, 2021 Filed Feb 1, 2021 21:39 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 3,821 | $6.36 | $24,301.56 |
DisclosureSEC source: 0001209191-21-006601 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,439 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $6.33 to $6.49. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 17:29 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 2,630 | $4.41 | $11,598.30 |
DisclosureSEC source: 0001209191-21-004931 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,260 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $4.35 to $4.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 2, 2020 16:44 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 2,050 | $3.21 | $6,580.50 |
DisclosureSEC source: 0001209191-20-056424 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,890 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $3.16 to $3.24. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 16:21 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-020266 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,940 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on January 31, 2021. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 17:33 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 1,269 | $5.92 | $7,512.48 |
DisclosureSEC source: 0001209191-20-004717 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,940 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $5.90 to $5.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 16:48 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001209191-19-055838 · doc4.xml · derivative · entry 2 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-11-06 F2 · derivative.exercise_date: The Option shares shall vest as follows: 1/48th of the option shares shall vest on December 1, 2019 and 1/48th shall vest monthly thereafter, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| November 07, 2019 Filed Nov 8, 2019 16:48 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-055838 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,209 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 1/4th on each of 11/1/20, 11/1/21, 11/1/22 and 11/1/23, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| July 22, 2019 Filed Jul 23, 2019 18:06 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 1,082 | $6.00 | $6,492.00 |
DisclosureSEC source: 0001209191-19-042978 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,209 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 16:31 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001209191-19-024242 · doc4.xml · derivative · entry 2 Prentiss Christopher B · CIK 0001717583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2029-04-07 F2 · derivative.exercise_date: The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with May 1, 2019, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 16:31 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-024242 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,291 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2020, March 20, 2021, March 20, 2022 and March 20, 2023, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 16:43 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 1,185 | $8.00 | $9,480.00 |
DisclosureSEC source: 0001209191-19-020779 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,541 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $7.94 to $8.03. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 16:25 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-064320 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,726 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on July 20, 2019 and January 20, 2020 and 50% of the total number of Restricted Stock Units will vest on January 20, 2021, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 17:09 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 228 | $7.51 | $1,712.28 |
DisclosureSEC source: 0001209191-18-064120 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,226 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $7.50 to $7.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 696 shares purchased on 5/31/18 through the issuer's employee stock purchase plan. Read SEC document |
| March 21, 2018 Filed Mar 22, 2018 17:54 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | SaleCommon Stock | 567 | $25.98 | $14,730.66 |
DisclosureSEC source: 0001209191-18-021314 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,758 F1 · kind: Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units. F2 · price: The shares were sold at prices ranging from $25.83 to $26.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2018 Filed Mar 9, 2018 20:51 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $25.66 | $0.00 |
DisclosureSEC source: 0001209191-18-018674 · doc4.xml · derivative · entry 2 Prentiss Christopher B · CIK 0001717583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-03-05 F3 · derivative.exercise_date: The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with April 1, 2018, subject to Reporting Person's Continuous Service as of each such date. Read SEC document |
| March 06, 2018 Filed Mar 9, 2018 20:51 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-018674 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,325 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2019, March 20, 2020, March 20, 2021 and March 20, 2022, subject to Reporting Person's Continuous Service as of each such date. F2 · balance_after: Includes 920 shares purchased on 11/30/17 through the issuer's employee stock purchase plan. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 19:00 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $23.11 | $0.00 |
DisclosureSEC source: 0001209191-17-056550 · doc4.xml · derivative · entry 2 Prentiss Christopher B · CIK 0001717583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-10-05 F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in equal monthly installments on the 1st of every month over four years with the first vesting on October 1, 2017. Read SEC document |
| October 06, 2017 Filed Oct 10, 2017 19:00 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056550 · doc4.xml · nonDerivative · entry 1 Prentiss Christopher B · CIK 0001717583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,405 F1 · shares: Represents the grant of restricted stock units that vest 1/4th on each of December 20, 2018, December 20, 2019, December 20, 2020 and December 20, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.